Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma

Year: 2014

Type: article

Abstract: There are limited data on the outcomes of autologous or allogeneic hematopoietic cell transplantation (HCT) in diffuse large B cell lymphoma transformed from follicular lymphoma. We analyzed transplantation outcomes in 141 subjects with biopsy-proven diffuse large B-cell lymphoma transformed from follicular lymphoma reported to the Center for International Blood and Marrow Transplant Research between 1990 and 2009. Two groups were identified: autologous HCT (auto-HCT; n = 108) and allogeneic HCT (allo-HCT; n = 33). Fewer auto-HCTs were done for transformed follicular lymphoma in 2003 to 2009, with a shift favoring allo-HCT. Auto-HCT was associated with a 1-year nonrelapse mortality (NRM) of 8% (95% confidence interval [CI], 4% to 14%), 5-year progression-free survival of 35% (95% CI, 26% to 45%), and 5-year overall survival of 50% (95% CI, 40% to 59%). In contrast, allo-HCT was associated with a 1-year NRM of 41% (95% CI, 23% to 58%), 5-year progression-free survival of 18% (95% CI, 6% to 35%), and 5-year overall survival of 22% (95% CI, 8% to 41%). Auto-HCT for transformed follicular lymphoma achieves sustained remission in a high proportion of subjects. The high NRM of allo-HCT offset any benefit that might be associated with this transplantation modality.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2014.03.014

Institutions: Stony Brook University Hospital, Stony Brook Medicine, Stony Brook University, Froedtert Hospital, West Virginia University, West Virginia University Hospitals, Medical College of Wisconsin, Banner MD Anderson Cancer Center, Alfaisal University, King Faisal Specialist Hospital & Research Centre, Dana-Farber Cancer Institute, University of South Florida, Moffitt Cancer Center, University of Minnesota Medical Center, Cleveland Clinic, New York Medical College, Barnes-Jewish Hospital, Harvard University, Massachusetts General Hospital, Medical University of South Carolina, Henry Ford Health, Henry Ford Hospital, The University of Texas at San Antonio Health Science Center, South Texas Veterans Health Care System, Oregon Health & Science University, Royal Prince Alfred Hospital, Johns Hopkins University, Johns Hopkins All Children's Hospital, Fred Hutch Cancer Center, University of Florida Health, University of Florida, Mayo Clinic, Baylor College of Medicine, Bethesda Hospital East, Louisiana State University Health Sciences Center Shreveport, University of Massachusetts Chan Medical School, UMass Memorial Medical Center, Vanderbilt University Medical Center, Phoenix Children's Hospital, Mayo Clinic in Arizona, Mayo Clinic Hospital, Duke University, Duke Medical Center, Memorial Sloan Kettering Cancer Center, Maastricht University Medical Centre, Maastricht University, University of Cambridge, Addenbrooke's Hospital, Nebraska Medical Center, Emory University, Winship Cancer Institute, Yeshiva University, Lady of Mercy Medical Center, Imperial College London

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650

Funders: National Institutes of Health, National Heart, Lung, and Blood Institute, National Cancer Institute, National Institute of Allergy and Infectious Diseases, National Center for Advancing Translational Sciences

Awards: University of Minnesota Clinical and Translational Science Institute (UMN CTSI), G7088928756, G777363952, A Data Resource for Blood and Marrow Transplants and Adoptive Cellular Therapy Research

OpenAlex ID: W2066345249